He Shikun, Ding Yi, Zhou Jiehao, Krasnoperov Valery, Zozulya Sergey, Kumar S Ram, Ryan Stephen J, Gill Parkash S, Hinton David R
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, USA.
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4772-9. doi: 10.1167/iovs.05-0502.
The purpose of this study was to evaluate the effect of a soluble monomeric form of the EphB4 extracellular domain (sEphB4) on choroidal endothelial cell (CEC) migration and tube formation and on experimental laser-induced choroidal neovascularization (CNV).
EphrinB2 and EphB4 expression in CECs was investigated by Western blot analysis and immunohistochemistry. Effects of sEphB4 (0.5-3 microg/mL) on CEC migration were evaluated with a modified Boyden chamber assay. Tube formation was assayed in CEC cultures in collagen gel. CNV was induced in rats by laser photocoagulation. The effects of intravitreal injection of sEphB4 on CNV development were evaluated at day 14 by fluorescein angiography (FA), confocal volumetric analysis of isolectin-B4 labeled flatmounts, and histologic examination of CNV membranes.
CEC cells express both EphB4 and EphrinB2, according to Western blot analysis. Immunohistochemical sections of rat eye showed immunoreactivity for both EphB4 and EphrinB2 in the choroidal endothelium. sEphB4 reduced CEC migration in response to vascular endothelial growth factor (P < 0.01). Similarly, sEphB4 inhibited CEC tube formation in a dose-dependent manner. EphB4, and to a lesser extent EphrinB2, were detected on vascular channels within laser-induced CNV membranes. Intravitreal injection of sEphB4 inhibited laser-induced CNV formation. CNV membranes showed a reduction in leakage score (P < 0.05), and membrane volumes were reduced in size (P < 0.05). Histologic analysis revealed that vascularity was reduced in sEphB4-treated membranes.
Recombinant soluble monomeric EphB4 exerts an inhibitory effect on choroidal angiogenesis in vitro and in vivo. It should be further evaluated for its potential as a novel therapy for CNV.
本研究旨在评估可溶性单体形式的EphB4细胞外结构域(sEphB4)对脉络膜内皮细胞(CEC)迁移、管腔形成以及对实验性激光诱导脉络膜新生血管(CNV)的影响。
通过蛋白质免疫印迹分析和免疫组织化学研究CEC中EphrinB2和EphB4的表达。用改良的Boyden小室试验评估sEphB4(0.5 - 3微克/毫升)对CEC迁移的影响。在胶原凝胶中的CEC培养物中检测管腔形成。通过激光光凝在大鼠中诱导CNV。在第14天通过荧光素血管造影(FA)、异凝集素-B4标记的平铺标本的共聚焦体积分析以及CNV膜的组织学检查评估玻璃体内注射sEphB4对CNV发展的影响。
根据蛋白质免疫印迹分析,CEC细胞同时表达EphB4和EphrinB2。大鼠眼的免疫组织化学切片显示脉络膜内皮中EphB4和EphrinB2均有免疫反应性。sEphB4可降低血管内皮生长因子诱导的CEC迁移(P < 0.01)。同样,sEphB4以剂量依赖性方式抑制CEC管腔形成。在激光诱导的CNV膜内的血管通道上检测到EphB4,EphrinB2的表达较少。玻璃体内注射sEphB4可抑制激光诱导CNV的形成。CNV膜的渗漏评分降低(P < 0.05),膜体积减小(P < 0.05)。组织学分析显示,sEphB4处理的膜中的血管化程度降低。
重组可溶性单体EphB4在体外和体内对脉络膜血管生成均有抑制作用。应进一步评估其作为CNV新型治疗方法的潜力。